$19.73 -$0.62 (-3.0%)

04:00 PM EDT on 10/18/19

Editas Medicine (NASDAQ:EDIT)

CAPS Rating: 4 out of 5

Current Price $19.73 Mkt Cap $965.3M
Open $20.21 P/E Ratio 0.00
Prev. Close $20.35 Div. (Yield) $0.00 (0.0%)
Daily Range $19.61 - $20.50 Volume 387,660
52-Wk Range $19.00 - $28.15 Avg. Daily Vol. 582,604


How do you think NASDAQ:EDIT will perform against the market?

Add Stock to CAPS Watchlist

All Players

236 Outperform
10 Underperform

All-Star Players

69 Outperform
2 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:EDIT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

rhallbick (88.45)
Submitted April 15, 2018

Editas Medicine (NASDAQ: EDIT) is a biotech specializing in CRISPR-Cas9 research and development. CRISPR has promise for the treatment of patients with genetically defined diseases by correcting their disease?causing genes.CRISPR is an acronym for… More

btechrisk11 (< 20)
Submitted April 15, 2018

Still a lot to learn for CRISPR technology to translate to clinic safely. CRISPR can be fairly selective but there was a recent journal article suggesting many people have antibodies/immune responses against some of the CRISPR elements.



Fools bullish on NASDAQ:EDIT are also bullish on:

Fools bearish on NASDAQ:EDIT are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EDIT.


Member Avatar SurfingCabarete (< 20) Submitted: 7/9/2019 12:17:57 PM : Outperform Start Price: $23.84 NASDAQ:EDIT Score: -17.73

bet on gene editing


Member Avatar WilliamEbonics (64.21) Submitted: 5/20/2019 5:28:14 PM : Underperform Start Price: $22.17 NASDAQ:EDIT Score: +15.34

The Stock continues a downward drift, while money also continues to exit the stock over an extended period of time.


Member Avatar MarkFitzFool (43.49) Submitted: 5/11/2019 3:08:22 PM : Outperform Start Price: $24.45 NASDAQ:EDIT Score: -24.90

It's been a bumpy ride for Editas over the past few years, but such is the nature of being a developmental stage biotech company. What sets Editas apart is their leadership. Feng Zhang, one of the developers of both CRISPR and optogenetics, is a co-founder, as is George Church, one of the most famous scientists in the world and a pioneer of both synthetic biology and personalized genomics. Editas is early-stage, and inherently risky, but I'm extremely confident that they will prevail. They have a robust developmental and preclinical pipeline with therapies for Beta-Thalassemia, Sickle Cell, DMD, Cystic Fibrosis, genetic diseases of the eye and liver, CAR-T for cancer therapy, etc. Will they be the first to market with one of their cutting-edge non-CAR-T gene-editing therapies? Likely not (I think bluebird bio will beat them), but they have many promising shots on goal that position them to be a leader in the space. Furthermore, The Broad Institute holds several CRISPR patents, and both Zhang and Church are members of said institute. I foresee Editas being one the future's top companies for personalized genetic therapies.


Find the members with the highest scoring picks in EDIT.

Score Leader


PAGEBOY73 (99.21) Score: +120.59

The Score Leader is the player with the highest score across all their picks in EDIT.

Member Name Member
Call Time
Score Commentary
SeriousK 28.94 3/9/2016 Underperform 5Y $42.70 -53.79% +49.59% +103.38 0 Comment
TimeToBuy 87.72 3/10/2016 Underperform 5Y $32.50 -39.29% +49.14% +88.43 0 Comment
nobody2013 < 20 3/10/2016 Underperform NS $26.79 -26.35% +50.41% +76.76 1 Comment
willism 32.92 1/29/2018 Underperform 3Y $40.64 -51.45% +4.35% +55.80 0 Comment
btechrisk11 < 20 4/16/2018 Underperform 3Y $34.93 -43.52% +11.69% +55.21 1 Comment
LastPlaceLenny 57.70 3/15/2019 Underperform 1Y $24.03 -17.89% +6.30% +24.20 1 Comment
chushogi 68.49 1/9/2017 Underperform 5Y $18.05 +9.31% +31.43% +22.12 0 Comment
WilliamEbonics 64.21 5/21/2019 Underperform 3Y $22.17 -11.01% +4.33% +15.34 1 Comment
LazyHarlequin 96.08 12/24/2018 Underperform 5Y $18.00 +9.61% +24.76% +15.15 1 Comment
freemarketmike < 20 6/7/2017 Outperform 5Y $15.43 +27.84% +22.45% +5.39 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EDIT.